NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: A meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 589-595

  Wang, P Y ^a,b   Xie, S Y ^a   Hao, Q ^c   Zhang, C ^a   Jiang, B F ^b  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c Binzhou Central Hospital   (China)

Author keywords

Drug induced liver injury; Meta analysis; N acetyltransferase 2; Polymorphism; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ASIAN; DRUG ACETYLATION; GENE; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LUNG TUBERCULOSIS; META ANALYSIS; N ACETYLTRANSFERASE 2 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; TOXIC HEPATITIS;

ANTITUBERCULAR AGENTS; ARYLAMINE N-ACETYLTRANSFERASE; DRUG-INDUCED LIVER INJURY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; RISK FACTORS; TUBERCULOSIS;

EID: 84859706085     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0377     Document Type: Review

References (46)

1. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line anti-tuberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167: 1472-1477. (Pubitemid 37363354)
2. Lundkvist J, Jonsson B. Pharmacoeconomics of adverse drug reactions. Fundam Clin Pharmacol 2004; 18: 275-280. (Pubitemid 38758694)
3. Parrish A G, Robson S C, Trey C, et al. Retrospective survey of drug-induced liver disease at Groot Schuur Hospital, Cape Town - 1983-1987. S Afr Med J 1990; 77: 199-202. (Pubitemid 20110337)
4. Wu J C, Lee S D, Yeh P F, et al. Isoniazid-rifampin-induced hepatitis in hepatitis B carriers. Gastroenterology 1990; 98: 502-504.
5. Farrell G C. Drug-induced hepatic injury. J Gastroenterol Hepatol 1997; 12: S242-S250. (Pubitemid 27504899)
6. Durand F, Bernuau J, Pessayre D, et al. Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid. Hepatology 1995; 21: 929-932.
7. Singh J, Garg P K, Thakur V S, et al. Anti-tubercular treatment induced hepatotoxicity: does acetylator status matter? Indian J Physiol Pharmacol 1995; 39: 43-46.
8. Pande J N, Singh S P N, Khilnani G C, et al. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study. Thorax 1996; 51: 132-136. (Pubitemid 26060649)
9. Acharya S K, Dasarathy S, Kumer T L, et al. Fulminant hepatitis in a tropical population: clinical course, cause, and early predictors of outcome. Hepatology 1996; 23: 1448-1455. (Pubitemid 26181228)
10. Wong W M, Wu P C, Yuen M F, et al. Anti-tuberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000; 31: 201-206.
11. Dossing M, Wilcke J T, Askgaard D S, et al. Liver injury during anti-tuberculosis treatment: an 11-year study. Tubercle Lung Dis 1996; 77: 335-340. (Pubitemid 26258538)
12. Devoto F M, Gonzalez C, Iannantuono R, et al. Risk factors for hepatotoxicity induced by anti-tuberculosis drugs. Acta Physiol Pharmacol Ther Latinoam 1997; 47: 197-202. (Pubitemid 28123845)
13. Ungo J R, Jones D, Ashkin D, et al. Anti-tuberculosis drugi nduced hepatotoxicity. The role of hepatitis C virus and the human immunodefiiency virus. Am J Respir Crit Care Med 1998; 157 (6 Pt 1): 1871-1876.
14. Jasmer R M, Saukkonen J J, Blumberg H M, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-647. (Pubitemid 35176096)
15. Singh J, Arora A, Garg P K. Anti-tuberculosis treatment-induced hepatotoxicity: role of predictive factors. Postgrad Med J 1995; 71: 359-362.
16. Shakya R, Rao B S, Shrestha B. Incidence of hepatotoxicity due to antitubercular medicines and assessment of risk factors. Ann Pharmacother 2004; 38: 1074-1079. (Pubitemid 38657755)
17. Ohno M, Yamaguchi I, Yamamoto I, et al. Slow N-acetyltransferase 2 genotype affects the incidence of isoniazid and rifampicin-induced hepatotoxicity. Int J Tuberc Lung Dis 2000; 4: 256-261. (Pubitemid 30151575)
18. Roy B, Chowdhury A, Kundu S, et al. Increased risk of anti-tuberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 'null' mutation. J Gastroenterol Hepatol 2001; 16: 1033-1037. (Pubitemid 32947147)
19. Huang Y S, Chern H D, Su W J, et al. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor of anti-tuberculosis drug-induced hepatitis. Hepatology 2002; 35: 883-889.
20. Huang Y S, Chern H D, Su W J, et al. Cytochrome P450 2E1 genetic polymorphism and the susceptibility to anti-tuberculosis drug-induced hepatitis. Hepatology 2003; 37: 924-930.
21. Roy B. Anti-tuberculosis drug induced hepatotoxicity and g enetic polymorphisms in drug-metabolizing genes. Curr P harmacogenomics 2003; 1: 101-109.
22. Hussain Z, Kar P, Husain S A. Anti-tuberculosis drug-induced hepatitis: risk factors, prevention and management. Indian J Exp Biol 2003; 41: 1226-1232. (Pubitemid 37379303)
23. Shimizu Y, Dobashi K, Mita Y, et al. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb) 2006; 86: 374-381. (Pubitemid 44189952)
24. Vuilleumier N, Rossier M F, Chiappe A, et al. CYP2E1 genotype and isoniazid-induced hepatotoxicity in patients treated for latent tuberculosis. Eur J Clin Pharmacol 2006; 62: 423-429. (Pubitemid 44069498)
25. Cho H J, Koh W J, Ryu Y J, et al. Genetic polymorphisms of NAT2 and CYP2E1 associated with anti-tuberculosis drugi nduced hepatotoxicity in Korean patients with pulmonary tuberculosis. Tuberculosis (Edinb) 2007; 87: 551-556.
26. Higuchi N, Tahara N, Yanagihara K, et al. NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis. World J Gastroenterol 2007; 13: 6003-6008. (Pubitemid 350252844)
27. Bozok Cetintaş V, Erer O F, Kosova B, et al. Determining the relation between N-acetyltransferase-2 acetylator phenotype and anti-tuberculosis drug-induced hepatitis by molecular biologic tests. Tuberk Toraks 2008; 56: 81-86.
28. Possuelo L G, Castelan J A, de Brito T C, et al. Association of slow N-acetyltransferase 2 profile and anti-TB drug-induced hepatotoxicity in patients from southern Brazil. Eur J Clin Pharmacol 2008; 64: 673-681.
29. Sun F, Chen Y, Xiang Y, Zhan S. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 2008; 12: 994-1002.
30. Lee S-W, Chung L S-C, Huang H-H, et al. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis. Int J Tuberc Lung Dis 2010; 14: 622-626.
31. Khalili H, Fouladdel S, Sistanizad M, Hajiabdolbaghi M, Azizi E. Association of N-acetyltransferase-2 genotypes and anti-tuberculosis induced liver injury; first case-controlled study from Iran. Curr Drug Saf 2011; 6: 17-22.
32. Bose P D, Sarma M P, Medhi S, et al. Role of polymorphic N-acetyltransferase 2 and cytochrome P4502E1 gene in anti-tuberculosis treatment-induced hepatitis. J Gastroenterol Hepatol 2011; 26: 312-318.
33. Yamada S, Tang M, Richardson K, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics 2009; 10: 1433-1445.
34. Kim S H, Kim S H, Bahn J W, et al. Genetic polymorphisms of drug-metabolizing enzymes and anti-TB drug-induced hepatitis. Pharmacogenomics 2009; 10: 1767-1779.
35. An H R, Wu X Q, Wang Z Y, et al. The associations of polymorphism of N-acetyltransferase 2 gene is associated with anti-tuberculosis drug-induced hepatotoxicity in tuberculosis patients. Zhonghua Yu Fang Yi Xue Za Zhi 2011; 45: 36-40.
36. Sotsuka T, Sasaki Y, Hirai S, et al. Association of isoniazidm etabolizing enzyme genotypes and isoniazid-induced hepatotoxicity in tuberculosis patients. In Vivo 2011; 25: 803-812.
37. Smith C A, Smith G, Wolf C R. Genetic polymorphisms in x enobiotic metabolism. Eur J Cancer 1994; 30A: 1921-1935.
38. Hein D W. Molecular genetics and function of NAT1 and NAT2: role in aromatic amine metabolism and carcinogenesis. Mutat Res 2002; 506-507: 65-77. (Pubitemid 35286541)
39. Mitchell J R, Thorgeirsson U P, Black M, et al. Increased i ncidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther 1975; 18: 70-79.
40. Yamamoto T, Suou T, Hirayama C. Elevated serum aminotransferase induced by isoniazid in relation to isoniazid acetylator phenotype. Hepatology 1986; 6: 295-298. (Pubitemid 16144882)
41. Little J, Bradley L, Bray M S, et al. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am J Epidemiol 2002; 156: 300-310. (Pubitemid 34857997)
42. Benichou C. Criteria of drug-induced liver disorders: report of an International Consensus Meeting. J Hepatol 1990; 11: 272-276.
43. Higgins J P, Thompson S G, Deeks J J, et al. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-560. (Pubitemid 37088507)
44. Begg C B, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101.
45. Egger M, Davey S G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634. (Pubitemid 27387172)
46. García-Closas M, Malats N, Silverman D, et al. NAT2 slow acetylation and GSTM1 null genotypes increase bladder cancer risk: results from the Spanish Bladder Cancer Study and meta-analyses. Lancet 2005; 366: 649-659. (Pubitemid 41176017)